Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.58 -1.0%	$14.25	$9.57 ▼ $30.41	$2.15B	0.96	1.53 million shs	446,354 shs
KNSA Kiniksa Pharmaceuticals	$28.21 -0.3%	$25.12	$17.38 ▼ $30.69	$2.06B	0.06	515,271 shs	263,866 shs
NAMS NewAmsterdam Pharma	$19.36 -4.2%	$18.19	$14.06 ▼ $27.29	$2.17B	-0.03	683,178 shs	985,201 shs
RLAY Relay Therapeutics	$3.26 +1.1%	$2.96	$1.78 ▼ $10.72	$559.43M	1.59	2.07 million shs	436,174 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-6.37%	+0.19%	+0.90%	-39.09%
KNSA Kiniksa Pharmaceuticals	0.00%	-6.38%	+7.81%	+23.20%	+50.77%
NAMS NewAmsterdam Pharma	0.00%	+0.35%	+7.04%	-13.41%	+5.32%
RLAY Relay Therapeutics	0.00%	-4.17%	+14.59%	-8.26%	-55.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.7022 of 5 stars	3.4	1.0	3.4	3.3	2.5	0.0
KNSA Kiniksa Pharmaceuticals	3.2361 of 5 stars	3.5	3.0	0.0	2.9	3.3	0.6
NAMS NewAmsterdam Pharma	2.9594 of 5 stars	3.5	2.0	0.0	2.5	5.0	0.0
RLAY Relay Therapeutics	2.201 of 5 stars	3.4	2.0	0.0	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	179.32% Upside
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	37.22% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	129.21% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	458.19% Upside

Current Analyst Ratings Breakdown

Latest RLAY, ARWR, NAMS, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
4/29/2025	KNSA Kiniksa Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/17/2025	RLAY Relay Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00
4/16/2025	KNSA Kiniksa Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	3.96	N/A	N/A	$1.54 per share	10.16
KNSA Kiniksa Pharmaceuticals	$481.17M	4.29	N/A	N/A	$6.23 per share	4.54
NAMS NewAmsterdam Pharma	$47.14M	44.68	N/A	N/A	$3.50 per share	5.36
RLAY Relay Therapeutics	$7.68M	70.66	N/A	N/A	$5.90 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	N/A	N/A	-236.60%	-64.09%	8/6/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	113.10	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)
RLAY Relay Therapeutics	-$341.97M	-$2.23	N/A	N/A	N/A	N/A	-45.75%	-40.75%	8/5/2025 (Estimated)

Latest RLAY, ARWR, NAMS, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
RLAY Relay Therapeutics	N/A	18.42	18.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
KNSA Kiniksa Pharmaceuticals	53.95%
NAMS NewAmsterdam Pharma	89.89%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
KNSA Kiniksa Pharmaceuticals	53.48%
NAMS NewAmsterdam Pharma	20.84%
RLAY Relay Therapeutics	4.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	120.68 million	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.97 million	32.80 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	74.37 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	160.15 million	Optionable

RLAY, ARWR, NAMS, and KNSA Headlines

Recent News About These Companies

Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down - Here's What Happened

June 13 at 1:26 PM | marketbeat.com

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

June 11, 2025 | globenewswire.com

Relay Therapeutics (NASDAQ:RLAY) Trading 6.7% Higher - What's Next?

June 10, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts

June 10, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Growth in Short Interest

June 5, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Bank of America Corp DE

June 4, 2025 | marketbeat.com

Squarepoint Ops LLC Increases Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)

June 3, 2025 | marketbeat.com

Nuveen Asset Management LLC Increases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)

June 3, 2025 | marketbeat.com

Jane Street Group LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)

June 3, 2025 | marketbeat.com

Relay Therapeutics’ RLY-2608 Shows Promising 11-Month PFS in Breast Cancer

June 2, 2025 | msn.com

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

June 2, 2025 | globenewswire.com

Two Sigma Investments LP Sells 199,482 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 31, 2025 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Shares Up 5.1% - Here's What Happened

May 30, 2025 | marketbeat.com

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 29, 2025 | globenewswire.com

Relay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal year

May 29, 2025 | investing.com

Voloridge Investment Management LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 29, 2025 | marketbeat.com

Man Group plc Buys Shares of 173,605 Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 27, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by Millennium Management LLC

May 26, 2025 | marketbeat.com

Northern Trust Corp Buys 231,713 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 24, 2025 | marketbeat.com

What Makes Relay Therapeutics (RLAY) a New Buy Stock

May 23, 2025 | zacks.com

BNP Paribas Financial Markets Invests $987,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY, ARWR, NAMS, and KNSA Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.58 -0.16 (-1.02%)

As of 12:42 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Kiniksa Pharmaceuticals NASDAQ:KNSA

$28.21 -0.09 (-0.33%)

As of 12:42 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

NewAmsterdam Pharma NASDAQ:NAMS

$19.36 -0.85 (-4.21%)

As of 12:42 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Relay Therapeutics NASDAQ:RLAY

$3.26 +0.04 (+1.09%)

As of 12:42 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time